After determining PRDX5 as the most significant prognostic factor in the PRDX family, we developed a nomogram integrating PRDX5 expression with clinical features to better predict clinical outcomes in prostate cancer patients than 30 other 30 public gene signatures. This evidence concerns the gene PRDX5 and prostate carcinoma.